Beijing Leadman Biochemistry Co Ltd
Beijing Leadman Biochemistry Co.,Ltd. researches and develops, manufactures, and sells vitro diagnostic reagents and instruments, and biochemical raw materials in the People's Republic of China. The company offers biochemical raw materials, including enzymes, antigens, coenzymes, antibodies, buffers, enzyme substrates, culture mediums, stain agents, amino acids, and other products for biotechnolo… Read more
Beijing Leadman Biochemistry Co Ltd (300289) - Total Assets
Latest total assets as of September 2025: CN¥1.81 Billion CNY
Based on the latest financial reports, Beijing Leadman Biochemistry Co Ltd (300289) holds total assets worth CN¥1.81 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Beijing Leadman Biochemistry Co Ltd - Total Assets Trend (2008–2024)
This chart illustrates how Beijing Leadman Biochemistry Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Beijing Leadman Biochemistry Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Beijing Leadman Biochemistry Co Ltd's total assets of CN¥1.81 Billion consist of 60.8% current assets and 39.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 31.5% |
| Accounts Receivable | CN¥113.71 Million | 6.2% |
| Inventory | CN¥89.45 Million | 4.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥25.17 Million | 1.4% |
| Goodwill | CN¥73.53 Million | 4.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Beijing Leadman Biochemistry Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing Leadman Biochemistry Co Ltd's current assets represent 60.8% of total assets in 2024, a decrease from 64.2% in 2008.
- Cash Position: Cash and equivalents constituted 31.5% of total assets in 2024, up from 24.8% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 4.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 6.2% of total assets.
Beijing Leadman Biochemistry Co Ltd Competitors by Total Assets
Key competitors of Beijing Leadman Biochemistry Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cheelcare Inc.
V:CHER
|
Canada | CA$4.27 Million |
|
FluroTech Ltd
OTCQB:FLURF
|
USA | $282.20K |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩119.28 Billion |
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
Beijing Leadman Biochemistry Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Beijing Leadman Biochemistry Co Ltd generates 0.20x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Beijing Leadman Biochemistry Co Ltd is currently not profitable relative to its asset base.
Beijing Leadman Biochemistry Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.03 | 14.83 | 4.22 |
| Quick Ratio | 13.91 | 13.53 | 3.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.04 Billion | CN¥ 1.03 Billion | CN¥ 525.22 Million |
Beijing Leadman Biochemistry Co Ltd - Advanced Valuation Insights
This section examines the relationship between Beijing Leadman Biochemistry Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.31 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | -6.0% |
| Total Assets | CN¥1.82 Billion |
| Market Capitalization | $271.42 Million USD |
Valuation Analysis
Below Book Valuation: The market values Beijing Leadman Biochemistry Co Ltd's assets below their book value (0.15 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Beijing Leadman Biochemistry Co Ltd's assets decreased by 6.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Beijing Leadman Biochemistry Co Ltd (2008–2024)
The table below shows the annual total assets of Beijing Leadman Biochemistry Co Ltd from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.82 Billion | -5.98% |
| 2023-12-31 | CN¥1.94 Billion | -2.94% |
| 2022-12-31 | CN¥2.00 Billion | -14.96% |
| 2021-12-31 | CN¥2.35 Billion | +44.20% |
| 2020-12-31 | CN¥1.63 Billion | -4.99% |
| 2019-12-31 | CN¥1.71 Billion | -0.87% |
| 2018-12-31 | CN¥1.73 Billion | -1.41% |
| 2017-12-31 | CN¥1.75 Billion | +5.48% |
| 2016-12-31 | CN¥1.66 Billion | +0.25% |
| 2015-12-31 | CN¥1.66 Billion | +2.63% |
| 2014-12-31 | CN¥1.62 Billion | +29.92% |
| 2013-12-31 | CN¥1.24 Billion | +10.07% |
| 2012-12-31 | CN¥1.13 Billion | +209.09% |
| 2011-12-31 | CN¥365.66 Million | +41.34% |
| 2010-12-31 | CN¥258.71 Million | +69.09% |
| 2009-12-31 | CN¥153.00 Million | +34.32% |
| 2008-12-31 | CN¥113.91 Million | -- |